Premium
Hydroxychloroquine, COVID ‐19 and diabetes. Why it is a different story
Author(s) -
Stoian Anca Pantea,
Catrinoiu Doina,
Rizzo Manfredi,
Ceriello Antonio
Publication year - 2021
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.3379
Subject(s) - hydroxychloroquine , covid-19 , diabetes mellitus , medicine , action (physics) , virology , intensive care medicine , disease , endocrinology , infectious disease (medical specialty) , physics , quantum mechanics , outbreak
Hydroxychloroquine has been proposed for the cure of the COVID‐19 due to its anti‐inflammatory and anti‐viral action. People with diabetes are more prone to severe outcome if affected by COVID‐19 and the use of Hydroxychloroquine might have some benefit in this setting. However, the use of Hydroxychloroquine in diabetes deserves particular attention for its documented hypoglycemic action.